Novozymes A/S
NVZMF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$32.67B
Close$
$0.87
98.8% downside
Current Fair Value
98.8% downsideOvervalued by 98.8% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $32.67 Billion |
|---|---|
| Enterprise Value | - |
| Annual dividend | $1.02 |
| Dividend yield | 1.52% |
| Earnings per Share | $1.25 |
| Beta | 0.62 |
| Outstanding Shares | 466,246,618 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 41.58 |
|---|---|
| PEG | 4.97 |
| Price to Sales | 7.79 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
$0.62
Consensus analyst estimateRevenue Estimate
$1.26 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.75
Consensus analyst estimateRevenue Estimate
$1.29 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Novozymes A/S
11,098 employees
CEO: Ester Baiget
Established in 1925 and based in Bagsvaerd, Denmark, Novozymes A/S is a global provider of biological solutions, specializing in the development and sale of industrial enzymes, microorganisms, and probiotics. The company's reach extends ...